BE655242A - - Google Patents

Info

Publication number
BE655242A
BE655242A BE655242DA BE655242A BE 655242 A BE655242 A BE 655242A BE 655242D A BE655242D A BE 655242DA BE 655242 A BE655242 A BE 655242A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE655242A publication Critical patent/BE655242A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE655242D 1963-11-05 1964-11-04 BE655242A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1359863 1963-11-05
CH1210364 1964-09-17

Publications (1)

Publication Number Publication Date
BE655242A true BE655242A (fr) 1965-05-04

Family

ID=25709624

Family Applications (1)

Application Number Title Priority Date Filing Date
BE655242D BE655242A (fr) 1963-11-05 1964-11-04

Country Status (5)

Country Link
BE (1) BE655242A (fr)
DE (1) DE1467832A1 (fr)
FR (2) FR3797M (fr)
GB (1) GB1054278A (fr)
NL (1) NL6412822A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046041A1 (fr) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles destinés à être utilisés comme modulateurs de kinase dans le traitement du cancer
WO2014111356A1 (fr) 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Agonistes du récepteur d'oxytocine pour le traitement de maladies du système nerveux central

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3503609A1 (de) * 1985-02-02 1986-08-07 Bayer Ag, 5090 Leverkusen 5-sulfonamido-1-aryl-pyrazole
RU2579515C1 (ru) * 2014-12-29 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный технологический университет" (СибГТУ) Алкоксиметилзамещенные 1н-4-аминопиразолы

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046041A1 (fr) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles destinés à être utilisés comme modulateurs de kinase dans le traitement du cancer
US9416123B2 (en) 2011-09-30 2016-08-16 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2014111356A1 (fr) 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Agonistes du récepteur d'oxytocine pour le traitement de maladies du système nerveux central
CN104936593A (zh) * 2013-01-17 2015-09-23 霍夫曼-拉罗奇有限公司 用于治疗cns疾病的催产素受体激动剂
US9751870B2 (en) 2013-01-17 2017-09-05 Hoffman-La Roche Inc. Oxytocin receptor agonists for the treatment of CNS diseases
CN104936593B (zh) * 2013-01-17 2018-05-18 霍夫曼-拉罗奇有限公司 用于治疗cns疾病的催产素受体激动剂

Also Published As

Publication number Publication date
FR3797M (fr) 1965-12-27
NL6412822A (fr) 1965-05-06
DE1467832A1 (de) 1968-11-28
GB1054278A (en) 1967-01-11
FR4034M (fr) 1966-03-28

Similar Documents

Publication Publication Date Title
AR142945A1 (fr)
BE627012A (fr)
BE644971A (fr)
BE623315A (fr)
BE31062A (fr)
BE462764A (fr)
BE465565A (fr)
BE507458A (fr)
BE533484A (fr)
BE547422A (fr)
BE571209A (fr)
BE603935A (fr)
BE608372A (fr)
BE612803A (fr)
BE614220A (fr)
BE616247A (fr)
BE616830A (fr)
BE616967A (fr)
BE619061A (fr)
BE620325A (fr)
BE621232A (fr)
BE621517A (fr)
BE622160A (fr)
BE623117A (fr)
BE623220A (fr)